Retinitis Pigmentosa News and Research

RSS
Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
Retinitis Pigmentosa: Embryonic stem cells for replacement of diseased retinal cells and restoration of sight

Retinitis Pigmentosa: Embryonic stem cells for replacement of diseased retinal cells and restoration of sight

Low Vision of Michigan introduces new device for RP patients

Low Vision of Michigan introduces new device for RP patients

Researchers to test newest implant in restoring vision damaged by disease

Researchers to test newest implant in restoring vision damaged by disease

Researchers develop PEG-POD tool for gene therapy

Researchers develop PEG-POD tool for gene therapy

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

RP International benefit "The Eyes of Christmas" to be telecast to 160 million homes

RP International benefit "The Eyes of Christmas" to be telecast to 160 million homes

QLT commences enrollment in QLT091001 Phase Ib trial of LCA pediatric patients

QLT commences enrollment in QLT091001 Phase Ib trial of LCA pediatric patients

StemCells commences patient recruitment for a Phase I clinical trial of HuCNS-SC in PMD

StemCells commences patient recruitment for a Phase I clinical trial of HuCNS-SC in PMD

Study shows gene therapy can restore vision to children with Leber congenital amaurosis

Study shows gene therapy can restore vision to children with Leber congenital amaurosis

Electronic eye implant mimics human retina; restores partial vision

Electronic eye implant mimics human retina; restores partial vision

Retinal prosthesis restores partial vision to people who are totally blind

Retinal prosthesis restores partial vision to people who are totally blind

Human neural stem cells protect cone photoreceptors: StemCells preclinical data

Human neural stem cells protect cone photoreceptors: StemCells preclinical data

Mimetogen Pharmaceuticals completes its equity financing

Mimetogen Pharmaceuticals completes its equity financing

Research to explore diagnosis and treatment of rare diseases

Research to explore diagnosis and treatment of rare diseases

Electrically stimulating nerve cells can restore some vision

Electrically stimulating nerve cells can restore some vision

Artificial vision enhancers to reach the market by 2011

Artificial vision enhancers to reach the market by 2011

Subject enrollment in patients with retinitis pigmentosa for Phase 2 clinical study completed by R-Tech Ueno

Subject enrollment in patients with retinitis pigmentosa for Phase 2 clinical study completed by R-Tech Ueno

Scientists cultivate multiple types of retina cells from human stem cells

Scientists cultivate multiple types of retina cells from human stem cells

Gene therapy for retinitis pigmentosa

Gene therapy for retinitis pigmentosa

Saffron could stop blindness and cure eye disease

Saffron could stop blindness and cure eye disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.